中国生物制药：礼新医药与默沙东就LM-299合作顺利，将收到3亿美元技术转移里程碑付款

Group 1 - The core point of the article is that China Biopharma has successfully progressed in its collaboration with Merck on LM-299, with a milestone payment of $300 million expected to be received soon [1] - The technology transfer for LM-299 was completed in July 2023, and Merck anticipates recognizing the $300 million milestone payment in the third quarter [1] - In 2024, China Biopharma and Merck reached a global exclusive licensing agreement for LM-299, which includes an upfront payment of $588 million and potential milestone payments of up to $2.7 billion [1]